{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.2","upperLimit":"95.0","value":"86.7"},{"groupId":"OG001","lowerLimit":"47.8","upperLimit":"88.7","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Evaluate the response rate of patients receiving therapy. Patients are considered as having a response if their overall response is Partial Response or better using the proposed International Myeloma Working Group uniform response criteria. The percentage of patients achieving this and the exact 95% confidence interval will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Original portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG000","title":"Original Study - Revlimid, Cyclophosphamide, Prednisone"},{"description":"Extension portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG001","title":"Extension - Revlimid, Cyclophosphamide, Prednisone"}],"paramType":"NUMBER","populationDescription":"All patients receiving at least one dose of study drug and having at least one post-baseline visit","reportingStatus":"POSTED","timeFrame":"After 6 cycles","title":"Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}